UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 90

Sortiert nach

Prognostic value of pretreatment procalcitonin and neutrophil-lymphocyte ratio in extensive-stage small-cell lung cancer

Cancer biology & therapy, 2024-12, Vol.25 (1), p.2331273-2331273

2024

Link zum Volltext

Verfügbarkeit prüfen

Single-cell RNA sequencing reveals cellular and molecular immune profile in a Pembrolizumab-responsive PD-L1-negative lung cancer patient

Cancer Immunology, Immunotherapy, 2021-08, Vol.70 (8), p.2261-2274

2021

Link zum Volltext

Verfügbarkeit prüfen

Single-cell RNA sequencing reveals cellular and molecular immune profile in a Pembrolizumab-responsive PD-L1-negative lung cancer patient

Cancer Immunology, Immunotherapy, 2021-08, Vol.70 (8), p.2261-2274

2021

Link zum Volltext

Verfügbarkeit prüfen

hsa_circ_0003222 accelerates stemness and progression of non-small cell lung cancer by sponging miR-527

Cell death & disease, 2021-08, Vol.12 (9), p.807-807, Article 807

2021

Link zum Volltext

Verfügbarkeit prüfen

Dendritic cells combining with cytokine-induced killer cells synergize chemotherapy in patients with late-stage non-small cell lung cancer

Cancer Immunology, Immunotherapy, 2011-10, Vol.60 (10), p.1497-1502

2011

Link zum Volltext

Verfügbarkeit prüfen

Prognostic value of tumor cavitation in extensive-stage small-cell lung cancer patients treated with anlotinib

Journal of cancer research and clinical oncology, 2020-02, Vol.146 (2), p.401-406

2020

Link zum Volltext

Verfügbarkeit prüfen

Heterogeneity in PD-L1 expression between primary and metastatic lymph nodes: a predictor of EGFR-TKI therapy response in non-small cell lung cancer

Respiratory research, 2024-06, Vol.25 (1), p.233-11, Article 233

2024

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of anlotinib combined with PD‐1/PD‐L1 inhibitors as second‐line and subsequent therapy in advanced small‐cell lung cancer

Cancer medicine (Malden, MA), 2023-03, Vol.12 (5), p.5372-5383

2023

Link zum Volltext

Verfügbarkeit prüfen

Loss of BLK expression as a potential predictor of poor prognosis and immune checkpoint blockade response in NSCLC and contribute to tumor progression

Translational oncology, 2023-07, Vol.33, p.101671-101671, Article 101671

2023

Link zum Volltext

Verfügbarkeit prüfen

Safety and efficacy of multi-target TKI combined with nivolumab in check-point inhibitor-refractory patients with advanced NSCLC: a prospective, single-arm, two-stage study

BMC cancer, 2024-06, Vol.24 (1), p.1-715, Article 715

2024

Link zum Volltext

Verfügbarkeit prüfen

Decreased monocyte-to-lymphocyte ratio was associated with satisfied outcomes of first-line PD-1 inhibitors plus chemotherapy in stage IIIB-IV non-small cell lung cancer

Frontiers in immunology, 2023-01, Vol.14, p.1094378-1094378

2023

Link zum Volltext

Verfügbarkeit prüfen

Rationale and design of a phase II trial of dacomitinib in advanced non-small cell lung cancer patients with uncommon epidermal growth factor receptor mutations: a prospective and single arm study (DANCE study)

BMC cancer, 2022-03, Vol.22 (1), p.294-294, Article 294

2022

Link zum Volltext

Verfügbarkeit prüfen

On-treatment lung immune prognostic index is predictive for first-line PD-1 inhibitor combined with chemotherapy in patients with non-small cell lung cancer

Frontiers in immunology, 2023-05, Vol.14, p.1173025-1173025

2023

Link zum Volltext

Verfügbarkeit prüfen

Patterns of Recurrence and Survival Rate After Complete Resection of Pathological Stage N2 Small-Cell Lung Cancer

Frontiers in oncology, 2021-08, Vol.11, p.675354-675354

2021

Link zum Volltext

Verfügbarkeit prüfen

Osimertinib alone as second-line treatment for brain metastases (BM) control may be more limited than for non-BM in advanced NSCLC patients with an acquired EGFR T790M mutation

Respiratory research, 2021-05, Vol.22 (1), p.145-145, Article 145

2021

Link zum Volltext

Verfügbarkeit prüfen

TP53 Mutation Status and Biopsy Lesion Type Determine the Immunotherapeutic Stratification in Non-Small-Cell Lung Cancer

Frontiers in immunology, 2021-09, Vol.12, p.732125-732125

2021

Link zum Volltext

Verfügbarkeit prüfen

Clinical Features and Outcomes Analysis of Surgical Resected Pulmonary Large-Cell Neuroendocrine Carcinoma With Adjuvant Chemotherapy

Frontiers in oncology, 2020-12, Vol.10, p.556194-556194

2020

Link zum Volltext

Verfügbarkeit prüfen

Sonographic Features of Endobronchial Ultrasonography Predict Intrathoracic Lymph Node Metastasis in Lung Cancer Patients

The Annals of thoracic surgery, 2015-10, Vol.100 (4), p.1203-1209

2015

Link zum Volltext

Verfügbarkeit prüfen

Rationale and design of a multicenter, randomized phase II trial of durvalumab with or without multitarget tyrosine kinase inhibitor as maintenance treatment in extensive‐stage small‐cell lung cancer patients (DURABLE study)

The clinical respiratory journal, 2023-12, Vol.17 (12), p.1361-1367

2023

Link zum Volltext

Verfügbarkeit prüfen

Meeting Reports for “2011 International Symposium on Respiratory Endoscope and Lung Cancer ”

Zhongguo fei ai za zhi, 2011-07, Vol.14 (7)

ZHONG, Runbo

2011

Link zum Volltext

Verfügbarkeit prüfen

Association Between Obesity and Poor Prognosis in Patients Receiving Anlotinib for Advanced Non-Small Cell Lung Cancer

Frontiers in pharmacology, 2022-03, Vol.13, p.812555-812555

2022

Link zum Volltext

Verfügbarkeit prüfen

Association of metabolomics with PD-1 inhibitor plus chemotherapy outcomes in patients with advanced non-small-cell lung cancer

Journal for immunotherapy of cancer, 2024-04, Vol.12 (4), p.e008190

2024

Link zum Volltext

Verfügbarkeit prüfen

Novel blood-based hypomethylation of SH3BP5 is associated with very early-stage lung adenocarcinoma

Genes & Genomics, 2022, 44(4), , pp.445-453

2022

Link zum Volltext

Verfügbarkeit prüfen

Does surgically resected small‐cell lung cancer without lymph node involvement benefit from prophylactic cranial irradiation?

Thoracic cancer, 2020-05, Vol.11 (5), p.1239-1244

2020

Link zum Volltext

Verfügbarkeit prüfen

Mycobacteriumtuberculosis antigens repress Th1 immune response suppression and promotes lung cancer metastasis through PD-1/PDl-1 signaling pathway

Cell death & disease, 2019-01, Vol.10 (2)

2019

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 90

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(75)
Mit Volltextzugriff
(89)

Publikationsform

Artikel
(89)
Tagungsberichte
(1)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(61)
Life Sciences & Biomedicine
(59)
Oncology
(42)
Humans
(40)
Lung Cancer
(34)
Male
(21)
Lung Neoplasms - Pathology
(20)
Female
(19)
Chemotherapy
(18)
Non-Small Cell Lung Cancer
(18)
Lung Neoplasms - Drug Therapy
(16)
Respiratory System
(16)
Prognosis
(15)
Lung Neoplasms - Genetics
(14)
Metastasis
(14)
Middle Aged
(14)
Aged
(13)
Immunotherapy
(13)
Cancer Therapies
(12)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(12)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(1)
... seit 90 Tagen
(6)

Menü

Weitere Dienste

Einstellungen

Prognostic value of pretreatment procalcitonin and neutrophil-lymphocyte ratio in extensive-stage small-cell lung cancer

Single-cell RNA sequencing reveals cellular and molecular immune profile in a Pembrolizumab-responsive PD-L1-negative lung cancer patient

Single-cell RNA sequencing reveals cellular and molecular immune profile in a Pembrolizumab-responsive PD-L1-negative lung cancer patient

hsa_circ_0003222 accelerates stemness and progression of non-small cell lung cancer by sponging miR-527

Dendritic cells combining with cytokine-induced killer cells synergize chemotherapy in patients with late-stage non-small cell lung cancer

Prognostic value of tumor cavitation in extensive-stage small-cell lung cancer patients treated with anlotinib

Heterogeneity in PD-L1 expression between primary and metastatic lymph nodes: a predictor of EGFR-TKI therapy response in non-small cell lung cancer

Efficacy and safety of anlotinib combined with PD‐1/PD‐L1 inhibitors as second‐line and subsequent therapy in advanced small‐cell lung cancer

Loss of BLK expression as a potential predictor of poor prognosis and immune checkpoint blockade response in NSCLC and contribute to tumor progression

Safety and efficacy of multi-target TKI combined with nivolumab in check-point inhibitor-refractory patients with advanced NSCLC: a prospective, single-arm, two-stage study

Decreased monocyte-to-lymphocyte ratio was associated with satisfied outcomes of first-line PD-1 inhibitors plus chemotherapy in stage IIIB-IV non-small cell lung cancer

Rationale and design of a phase II trial of dacomitinib in advanced non-small cell lung cancer patients with uncommon epidermal growth factor receptor mutations: a prospective and single arm study (DANCE study)

On-treatment lung immune prognostic index is predictive for first-line PD-1 inhibitor combined with chemotherapy in patients with non-small cell lung cancer

Patterns of Recurrence and Survival Rate After Complete Resection of Pathological Stage N2 Small-Cell Lung Cancer

Osimertinib alone as second-line treatment for brain metastases (BM) control may be more limited than for non-BM in advanced NSCLC patients with an acquired EGFR T790M mutation

TP53 Mutation Status and Biopsy Lesion Type Determine the Immunotherapeutic Stratification in Non-Small-Cell Lung Cancer

Clinical Features and Outcomes Analysis of Surgical Resected Pulmonary Large-Cell Neuroendocrine Carcinoma With Adjuvant Chemotherapy

Sonographic Features of Endobronchial Ultrasonography Predict Intrathoracic Lymph Node Metastasis in Lung Cancer Patients

Rationale and design of a multicenter, randomized phase II trial of durvalumab with or without multitarget tyrosine kinase inhibitor as maintenance treatment in extensive‐stage small‐cell lung cancer patients (DURABLE study)

Meeting Reports for “2011 International Symposium on Respiratory Endoscope and Lung Cancer ”

Association Between Obesity and Poor Prognosis in Patients Receiving Anlotinib for Advanced Non-Small Cell Lung Cancer

Association of metabolomics with PD-1 inhibitor plus chemotherapy outcomes in patients with advanced non-small-cell lung cancer

Novel blood-based hypomethylation of SH3BP5 is associated with very early-stage lung adenocarcinoma

Does surgically resected small‐cell lung cancer without lymph node involvement benefit from prophylactic cranial irradiation?

Mycobacteriumtuberculosis antigens repress Th1 immune response suppression and promotes lung cancer metastasis through PD-1/PDl-1 signaling pathway

Suchergebnisse filtern